SynOx Therapeutics
Frank Bracken has a wealth of experience in the pharmaceutical industry, with a focus on quality management. Frank currently serves as Senior Vice President of Quality at SynOx Therapeutics, overseeing the quality organization and establishing quality management systems. Prior to their current role, Frank held positions at Zoetis as Director of Quality & Compliance, PPD as Associate Director | QP Clinical Quality Assurance, Innocoll Technologies Ltd., Taro Pharmaceuticals, and Elan Pharma. Frank holds an MSc (Hons) in Industrial Pharmaceutical Science from The Royal College of Physicians in Ireland.
This person is not in any teams
SynOx Therapeutics
SynOx Therapeutics Ltd was founded in November 2020 and is solely focused on developing emactuzumab for the treatment of diffuse tenosynovial giant cell tumours (TGCT) and other indications. SynOx is backed by a strong investor syndicate with long and successful backgrounds in building biopharma companies.